Clinical Trial: Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07368543) titled 'Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer' on Jan. 14.

Brief Summary: Currently, no phase III RCT has directly compared SG and T-DXd sequencing strategies, and the predictive role of biomarkers remains unclear. Additionally, there is no standard scoring system for Trop-2 expression. The ASCENT trial utilized an H-score method (H-score = 3x%IHC3+ + 2x%IHC2+ + 1x%IHC1+), with scores 200 defining low, medium, and high Trop-2 expression, respectively.This prospective study aims to: 1) Evaluate the efficacy of SG vs. T-DXd in HER2-low/Trop-2-high metastatic breast cancer, prioritizing SG for Trop-2-high pati...